Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Next Previous
Trial Profile

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zenocutuzumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver metastases; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus First in man; Therapeutic Use
  • Acronyms eNRGy
  • Sponsors Merus

    • Most Recent Events

    • 05 Mar 2024 According to a Merus media release, based on recent productive and collaborative discussions with the U.S. Food & Drug Administration, the company will have sufficient clinical data in the first half of 2024 to support potential Biologics License Application submissions in NRG1+ non-small cell lung cancer and NRG1+ pancreatic cancer.
    • 12 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
    • 12 Jan 2024 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top